Studie

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic L

Erkrankungsgruppe:

Leukämien und MDS, Lymphome

Organsystem:

Blut, Lymphsystem

Stadium:

Rückfall, Therapierefraktär

Standort:

Essen

EudraCT:

2017-003377-34

Prüfplan-Code:

54767414ALL2005

Phase:

II

Prüfsubstanz:

Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate

Sponsor:

Janssen Research & Development, LLC